GLP-1 for Men
Weight Loss, Testosterone, Muscle, and Cardiovascular Health
Men lose more weight on GLP-1 medications than women — and the benefits go far beyond the scale. GLP-1 therapy restores testosterone, improves erectile function, addresses sleep apnea, and dramatically reduces cardiovascular risk. Here is everything men need to know about Ozempic, Wegovy, Mounjaro, and Zepbound.
Men Lose More Weight on GLP-1s
In the landmark STEP 1 trial for semaglutide 2.4mg (Wegovy), men lost approximately 17% of body weight compared to approximately 14% for women over 68 weeks. This pattern holds across GLP-1 trials — men consistently outperform women in percentage weight loss, and even more so in absolute pounds lost given higher baseline body weight.
The reasons are physiological: men tend to carry more visceral (abdominal) fat, which is metabolically active and highly responsive to GLP-1's insulin-sensitizing effects. Men also typically have higher metabolic rates, meaning their caloric deficit from GLP-1-mediated appetite suppression translates to faster absolute weight loss.
GLP-1 Medications and Testosterone Restoration
Obesity is a leading cause of hypogonadism (low testosterone) in men. The mechanism is well understood: excess adipose tissue (fat) contains the enzyme aromatase, which converts testosterone into estrogen. The more body fat, the more testosterone gets converted — leaving men with low T and elevated estrogen levels.
Additionally, obesity creates a chronic low-grade inflammatory state and elevated insulin levels, both of which directly suppress testosterone production at the hypothalamic-pituitary-gonadal (HPG) axis. The result is a vicious cycle: low testosterone promotes fat gain, which further suppresses testosterone.
GLP-1 medications break this cycle. As body fat decreases — particularly visceral and subcutaneous fat — aromatase activity falls, insulin sensitivity improves, and inflammation resolves. Testosterone levels rise naturally, often substantially. Many men who were on testosterone replacement therapy (TRT) have successfully discontinued it after achieving significant weight loss with GLP-1 medications.
Symptoms of Low Testosterone That May Improve
- • Low energy and chronic fatigue
- • Reduced libido and sexual drive
- • Difficulty building or maintaining muscle
- • Increased body fat (especially abdominal)
- • Brain fog and poor concentration
- • Depressed mood and irritability
- • Reduced bone density
- • Poor sleep quality
Muscle Preservation: The Critical Priority for Men
Men's higher muscle mass is both an advantage and a vulnerability during GLP-1 therapy. On one hand, more muscle means a higher basal metabolic rate and greater capacity for fat burning. On the other hand, aggressive caloric restriction on GLP-1 medications can lead to significant muscle loss if protein intake and resistance training are inadequate.
Studies show that 25–40% of weight lost on GLP-1 monotherapy without resistance training is lean mass. For a man losing 50 lbs, this could mean 15–20 lbs of muscle loss — a serious metabolic setback that slows long-term weight maintenance.
Protein Target
Target 1.6g protein per kg of bodyweight (0.73g/lb). For a 200 lb man, that is 146g protein daily — achievable with deliberate food choices and protein supplementation.
Resistance Training
Resistance training 3–4x per week is non-negotiable. Compound lifts (squats, deadlifts, rows, presses) preserve more muscle than isolation exercises. Progressive overload should continue throughout the weight loss period.
Other Key Benefits for Men
Erectile Dysfunction Improvement
Erectile dysfunction is closely linked to obesity through three independent pathways: reduced blood flow from endothelial dysfunction, low testosterone from aromatase activity, and systemic inflammation. All three improve with GLP-1-driven weight loss.
Clinical data and patient reports consistently show significant improvements in erectile function and sexual satisfaction with 10–20% weight loss. For many men, this benefit alone is among the most transformative outcomes of GLP-1 therapy.
Sleep Apnea (Zepbound Approved)
Men have 2–3x higher prevalence of obstructive sleep apnea (OSA) than women. The FDA approved tirzepatide (Zepbound) specifically for moderate-to-severe OSA in adults with obesity in 2024 — the first medication approved for this indication.
SURMOUNT-OSA trial data showed tirzepatide reduced apnea-hypopnea index (AHI) by 62–63% — far exceeding CPAP-comparable thresholds. Many men on Zepbound for OSA report discontinuing CPAP therapy under physician guidance after weight loss.
Cardiovascular Risk Reduction
Men have significantly higher baseline cardiovascular risk than age-matched women. The SELECT trial for semaglutide demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with existing cardiovascular disease — results particularly relevant for male patients.
GLP-1 medications reduce blood pressure, improve lipid profiles, reduce inflammation markers (CRP, IL-6), and improve endothelial function — all of which disproportionately benefit male patients with elevated cardiovascular baseline risk.
Alcohol Craving Reduction
Men statistically consume significantly more alcohol than women, and alcohol's caloric density (7 kcal/g) represents a major obstacle to weight loss. GLP-1 receptors exist in reward pathways of the brain, and GLP-1 medications reduce dopamine-mediated cravings for alcohol and other rewarding substances.
Many men on GLP-1 therapy spontaneously report dramatically reduced desire to drink. This benefit — combined with direct weight loss — can compound results significantly for men who previously struggled to reduce alcohol intake.
Frequently Asked Questions
Should I continue TRT while taking a GLP-1 medication?
Do not discontinue TRT without physician guidance. However, if you are on TRT due to obesity-related hypogonadism (rather than primary testicular failure), your physician may want to monitor testosterone levels as you lose weight. Some men find their endogenous testosterone recovers enough to discontinue TRT — but this should always be guided by blood tests and a physician, not self-directed discontinuation.
Is Mounjaro or Ozempic better for men?
Both are highly effective. Tirzepatide (Mounjaro/Zepbound) consistently demonstrates greater weight loss than semaglutide (Ozempic/Wegovy) in head-to-head comparisons and large trials — approximately 21% vs 17% weight loss. For men specifically, Zepbound also has the sleep apnea indication, which is highly relevant given men's 2–3x higher OSA prevalence. Your physician will factor in your specific metabolic profile, diabetes status, and insurance coverage.
Will I lose strength on GLP-1 medications?
Only if you allow it to happen through inadequate protein intake and lack of resistance training. Men who maintain consistent resistance training and hit protein targets of 1.6g/kg during GLP-1 therapy can maintain or even improve strength while losing significant fat mass. The strength-to-weight improvement from fat loss typically outweighs any muscle mass reduction when training is consistent.